Phoenix Financial Ltd. Sells 41,678 Shares of Brainsway Ltd. Sponsored ADR $BWAY

Phoenix Financial Ltd. trimmed its stake in shares of Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) by 10.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 362,316 shares of the company’s stock after selling 41,678 shares during the quarter. Phoenix Financial Ltd.’s holdings in Brainsway were worth $4,764,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Huntleigh Advisors Inc. raised its holdings in Brainsway by 5.7% in the 2nd quarter. Huntleigh Advisors Inc. now owns 77,416 shares of the company’s stock valued at $1,018,000 after acquiring an additional 4,143 shares during the period. NewEdge Advisors LLC boosted its holdings in shares of Brainsway by 61.5% during the first quarter. NewEdge Advisors LLC now owns 19,828 shares of the company’s stock worth $188,000 after acquiring an additional 7,549 shares during the period. GAMMA Investing LLC grew its position in shares of Brainsway by 720.7% in the first quarter. GAMMA Investing LLC now owns 9,356 shares of the company’s stock valued at $89,000 after purchasing an additional 8,216 shares during the last quarter. Palumbo Wealth Management LLC bought a new position in shares of Brainsway during the first quarter worth approximately $111,000. Finally, ARK Investment Management LLC lifted its holdings in Brainsway by 7.3% during the 1st quarter. ARK Investment Management LLC now owns 188,328 shares of the company’s stock worth $1,783,000 after purchasing an additional 12,740 shares during the last quarter. Institutional investors own 30.11% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Weiss Ratings restated a “hold (c)” rating on shares of Brainsway in a research note on Tuesday, October 14th. Northland Securities boosted their target price on shares of Brainsway from $15.00 to $19.00 and gave the company an “outperform” rating in a research report on Thursday, August 14th. Wall Street Zen raised shares of Brainsway from a “hold” rating to a “buy” rating in a research report on Sunday, August 17th. Finally, HC Wainwright reissued a “buy” rating and issued a $17.00 price objective on shares of Brainsway in a report on Monday, August 25th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Brainsway Stock Up 2.5%

BWAY stock opened at $16.28 on Wednesday. Brainsway Ltd. Sponsored ADR has a 52 week low of $7.84 and a 52 week high of $17.00. The business has a 50-day simple moving average of $15.31 and a 200 day simple moving average of $12.29. The company has a market cap of $309.32 million, a PE ratio of 62.62 and a beta of 1.23.

Brainsway (NASDAQ:BWAY) last announced its quarterly earnings data on Wednesday, August 13th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $0.03. Brainsway had a net margin of 11.60% and a return on equity of 8.97%. The firm had revenue of $12.63 million for the quarter, compared to the consensus estimate of $12.34 million. Brainsway has set its FY 2025 guidance at EPS. On average, analysts anticipate that Brainsway Ltd. Sponsored ADR will post 0.08 EPS for the current fiscal year.

About Brainsway

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.